Geron rises on published Phase II imetelstat data

Geron Corp. (NASDAQ:GERN) climbed $0.40 (13%) to $3.45 on Thursday after data from two Phase II trials of imetelstat ( GRN163L) to treat essential thrombocythemia (ET) and myelofibrosis (MF) were published in The New England Journal of Medicine.

The ET data were in line with previously reported results. The 18-patient trial in ET patients who were refractory to or intolerant of conventional therapies showed imetelstat led to a hematologic response rate of 100% and a complete response rate of 89%. ...